SCHEMBL2567978

SCHEMBL2567978

O=C(Nc1ccc(OC(F)(F)F)cc1)Nc1cn(Cc2ccccc2)c(C(=O)O)n1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 6/20 0.53
PPARA Q07869 3/20 0.53
FPR2 P25090 1/20 0.50
IGF1R P08069 2/20 0.49
TP53 P04637 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
PPARG P37231 1/20 0.48
CACNA1G O43497 1/20 0.48
CACNA1H O95180 1/20 0.48
CACNA1I Q9P0X4 1/20 0.48
FAAH O00519 1/20 0.48
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
P2RY1 P47900 2/20 0.46
SERPINE1 P05121 2/20 0.45
TDP1 Q9NUW8 1/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1595202 0.91 EPHX2 (0.51) EPHX2PPARAIGF1RPPARGCACNA1G
SCHEMBL13197833 0.88 EPHX2 (0.48) EPHX2PPARAFPR2IGF1RTP53
SCHEMBL1594772 0.87 EPHX2 (0.56) EPHX2PPARAIGF1RPPARGFAAH
SCHEMBL2567980 0.87 EPHX2 (0.50) EPHX2PPARAFPR2IGF1RTP53
SCHEMBL13197836 0.86 IGF1R (0.47) EPHX2PPARAFPR2IGF1RTP53
SCHEMBL13197837 0.86 SMN1; SMN2 (0.48) EPHX2PPARAFPR2IGF1RTP53
SCHEMBL2881513 0.85 EPHX2 (0.49) EPHX2PPARAFPR2IGF1RPPARG
SCHEMBL13197832 0.85 EPHX2 (0.54) EPHX2PPARAIGF1RSMN1; SMN2FAAH
SCHEMBL13197917 0.84 MCHR1 (0.48) EPHX2PPARAFPR2IGF1RTP53
SCHEMBL13197896 0.84 EPHX2 (0.45) EPHX2PPARAFPR2IGF1RTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1732901-B1 ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND AICURIS GMBH & CO KG (DE) 2011-11-02 EP disclosed
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 US disclosed
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 US disclosed
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 US disclosed
EP-1732901-A1 ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND Bayer HealthCare AG (DE) 2006-12-20 EP disclosed
WO-2005092865-A1 ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND BAYER HEALTHCARE AG (DE) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds IRF3, EIF2AK2, ZC3HAV1 EPHX2 3922/4885PPARA 2490/4885FPR2 4423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.